BiotechTube

satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroids

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neuromyelitis Optica Spectrum Disorder

Conditions

Neuromyelitis Optica Spectrum Disorder

Trial Timeline

Mar 2, 2021 → May 28, 2024

NCT ID
NCT04660539

About satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroids

satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroids is a phase 3 stage product being developed by Roche for Neuromyelitis Optica Spectrum Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT04660539. Target conditions include Neuromyelitis Optica Spectrum Disorder.

What happened to similar drugs?

2 of 5 similar drugs in Neuromyelitis Optica Spectrum Disorder were approved

Approved (2) Terminated (1) Active (3)
✅Satralizumab 120 mgChugai PharmaceuticalApproved
✅InebilizumabAmgenApproved
🔄Satralizumab + Placebo + Baseline TreatmentChugai PharmaceuticalPhase 3
🔄Satralizumab + PlaceboChugai PharmaceuticalPhase 3
🔄SatralizumabRochePhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04660539Phase 3Completed

Competing Products

8 competing products in Neuromyelitis Optica Spectrum Disorder

See all competitors
ProductCompanyStageHype Score
Satralizumab 120 mgChugai PharmaceuticalApproved
35
Satralizumab + Placebo + Baseline TreatmentChugai PharmaceuticalPhase 3
40
Satralizumab + PlaceboChugai PharmaceuticalPhase 3
40
SatralizumabRochePhase 3
47
UPLIZNAAmgenPre-clinical
33
InebilizumabAmgenPhase 2
42
InebilizumabAmgenApproved
47
intravenous methylprednisoloneBrain BiotechPre-clinical
23